Rite Aid Ticker Symbol Update and Stock Outlook

Author

Reads 1.2K

Interior of a Vintage Pharmacy
Credit: pexels.com, Interior of a Vintage Pharmacy

Rite Aid's ticker symbol has undergone a change in the past, reflecting the company's evolution over time. The company's current ticker symbol is RAD, which was changed from RAD to RADS in 2008 due to a spin-off.

Rite Aid has been a publicly traded company since 1996, listed on the New York Stock Exchange (NYSE) under the ticker symbol RAD. This change in ticker symbol in 2008 was a result of a spin-off of its pharmacy benefit management (PBM) business, which was spun off into a separate company called Rite Aid Corporation (RADS).

As of 2022, Rite Aid's ticker symbol remains RAD.

Company News

Rite Aid's ticker symbol is RAD, which has been a part of the New York Stock Exchange since 1994.

Rite Aid has undergone significant changes in recent years, including the sale of its pharmacy benefit management business and the acquisition of EnvisionRx.

The company has also made efforts to improve its financial performance, with a focus on cost reduction and operational efficiency.

Choate Selected for Restructuring Deal of the Year Award

Pharmacist helps customer in elegant pharmacy with rotating product display.
Credit: pexels.com, Pharmacist helps customer in elegant pharmacy with rotating product display.

Choate has been selected to receive The M&A Advisor's Healthcare/Life Sciences Deal of the Year (Over $1B) Award for its role in the restructuring of Rite Aid.

Choate was chosen for this prestigious award due to its outstanding work in the Rite Aid transaction.

The M&A Advisor's Deal of the Year Awards recognize excellence in mergers and acquisitions, and Choate's selection is a testament to its expertise in this area.

Choate's role in the Rite Aid restructuring involved complex and high-stakes negotiations, ultimately resulting in a successful outcome.

Emerges from Bankruptcy, Names New CEO

Rite Aid has emerged from Chapter 11 bankruptcy.

The company has successfully completed its financial restructuring, marking a significant milestone.

Rite Aid has named Matt Schroeder, its current CFO, as its new CEO.

Essential Details

Rite Aid's ticker symbol is RADCQ, which it began trading under on October 17, 2023, after being delisted from the New York Stock Exchange.

The company filed for bankruptcy in October to address debt, close underperforming stores, and sell non-core business units.

Credit: youtube.com, 🚨Rite Aid Analysis - $RAD PRICE PREDICTION & TARGETS

Rite Aid's common stock was trading at $51.13 at the beginning of 1999, but the scandal took shares down to $21 within three months.

The company's stock price has been volatile over the years, struggling back to a high of $10 in 2001 but languishing for most of the next decade.

Rite Aid's bankruptcy case is expected to be completed by late April, pending final court approval for its restructuring plan.

The company's stock price crashed to a low of $0.28 during the Recession, but has shown signs of recovery in recent years with a gradual increase in its stock price, largely driven by strategic acquisitions and a focus on expanding its healthcare services.

Stock Information

Rite Aid's ticker symbol is RADCQ, which it started trading under on October 17, 2023, after being delisted from the New York Stock Exchange.

The company's stock price has been affected by various events, including a scandal that caused shares to plummet from $51.13 to as low as $1.50 in 1999-2001.

Credit: youtube.com, RITE AID $RAD, A BUY, SELL, HOLD | TECHNICAL ANALYSIS

Rite Aid's common stock was trading at $9 per share in October 2015 when Walgreens attempted to buy the company.

Here's a brief timeline of Rite Aid's stock price history:

Stock Outlook

Rite Aid's stock outlook is uncertain, with two likely futures: a takeover or a shift in strategy.

A takeover is unlikely, given past deals that failed to materialize.

Rite Aid has a large number of stores in many markets, which could be realigned to consumer trends with reasonable capital expenditure.

If executives can grow revenues and profits, share prices will move higher.

Analysts are bearish on Rite Aid's stock, with an average earnings estimate of -$1.35 per share.

Here are the analyst estimates:

Essential Information

Rite Aid has been in the pharmacy business since 1962, when Alex Grass founded the company in Scranton, Pennsylvania. It became the largest drugstore chain in the U.S. by 1995.

Rite Aid's stock price has had its ups and downs over the years. It peaked at $51.13 in 1999, but then plummeted to as low as $1.50 in 1999-2001 due to a scandal. The stock price struggled to recover, but eventually showed signs of recovery in the mid-2010s.

Intricate 18th-century pharmaceutical jars and bust at German Pharmacy Museum, Heidelberg.
Credit: pexels.com, Intricate 18th-century pharmaceutical jars and bust at German Pharmacy Museum, Heidelberg.

If you're a shareholder, you can sell your Rite Aid stock anytime the stock market is open. The availability of buyers and sellers will determine the price at which you can sell your shares.

Rite Aid's bankruptcy case is ongoing, but the company has reached a settlement with its lenders and the U.S. Department of Justice. This settlement is expected to be finalized by April 22nd.

Here's a brief timeline of Rite Aid's major events:

  • 1962: Rite Aid founded by Alex Grass
  • 1967: Rite Aid goes public with an IPO
  • 1995: Rite Aid becomes the largest drugstore chain in the U.S.
  • 1999-2001: Stock price plummets due to scandal
  • 2015: Walgreens attempts to buy Rite Aid
  • 2018: Albertsons attempts to buy Rite Aid, but ultimately cancels its acquisition
  • 2023: Rite Aid files for bankruptcy and is delisted from the NYSE

Frequently Asked Questions

Can I still buy Rite Aid stock?

Yes, you can still buy Rite Aid stock through various brokerage firms, including online services. Purchase options are widely available.

What is Rite Aid stock right now?

Rite Aid's current stock price is $0.65. Check our latest updates for the most current market information.

Abraham Lebsack

Lead Writer

Abraham Lebsack is a seasoned writer with a keen interest in finance and insurance. With a focus on educating readers, he has crafted informative articles on critical illness insurance, providing valuable insights and guidance for those navigating complex financial decisions. Abraham's expertise in the field of critical illness insurance has allowed him to develop comprehensive guides, breaking down intricate topics into accessible and actionable advice.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.